Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 10-18 years of age (both inclusive)~* Genetically confirmed diagnosis of Prader-Willi Syndrome~* Determined to be in nutritional phase 3 by clinical assessment based on Miller et al, 2011~Exclusion Criteria:~* Known genetic, hormonal, or chromosomal cause of cognitive impairment other than Prader-Willi Syndrome~* Presence of currently active psychotic symptoms~* Presence of any cardiovascular disorders, epilepsy, frequent migraines or severe asthma~* Previous diagnosis of autism spectrum disorder by a qualified healthcare provider~* Prior or concomitant use of a selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI), antipsychotic medication, wakefulness-promoting drug, or thyroid hormone unless dosage has been stable ≥6 months at time of screening

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- FE 992097 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).